Drug hypersensitivity: pharmacogenetics and clinical syndromes.
暂无分享,去创建一个
[1] S. Murad,et al. Association of HLA‐B*1502 allele with carbamazepine‐induced toxic epidermal necrolysis and Stevens–Johnson syndrome in the multi‐ethnic Malaysian population , 2011, International journal of dermatology.
[2] S. Mallal,et al. Pharmacogenetics of drug hypersensitivity. , 2010, Pharmacogenomics.
[3] R. Hui,et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. , 2010, Pharmacogenomics.
[4] M. Muramatsu,et al. HLA Class I markers in Japanese patients with carbamazepine‐induced cutaneous adverse reactions , 2010, Epilepsia.
[5] Yuan-Tsong Chen,et al. Genetic predisposition of life-threatening antiepileptic-induced skin reactions , 2010, Expert opinion on drug safety.
[6] C. Joshi,et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. , 2009, Indian journal of dermatology, venereology and leprology.
[7] S. Tiamkao,et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population , 2009, Pharmacogenetics and genomics.
[8] Yusuke Nakamura,et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients , 2009, Pharmacogenetics and genomics.
[9] B. Kuehn. FDA: Epilepsy drugs may carry skin risks for Asians. , 2008, JAMA.
[10] Yuan-Tsong Chen,et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis , 2008, Nature Medicine.
[11] K. Suphapeetiporn,et al. Carbamazepine and phenytoin induced Stevens‐Johnson syndrome is associated with HLA‐B*1502 allele in Thai population , 2008, Epilepsia.
[12] C. Sotozono,et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2008, Pharmacogenomics.
[13] E. Phillips,et al. A review of drug patch testing and implications for HIV clinicians , 2008, AIDS.
[14] A. Romano,et al. Association of tumor necrosis factor-α –308G>A polymorphism with IgE-mediated allergy to betalactams in an Italian population , 2008, The Pharmacogenomics Journal.
[15] S. Mallal,et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] S. Mallal,et al. HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.
[17] L. Naldi,et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs , 2008, Pharmacogenetics and genomics.
[18] H. Uchi,et al. Stevens-Johnson Syndrome, Drug-Induced Hypersensitivity Syndrome and Toxic Epidermal Necrolysis Caused by Allopurinol in Patients with a Common HLA Allele: What Causes the Diversity? , 2007, Dermatology.
[19] P. Kwan,et al. Association between HLA‐B*1502 Allele and Antiepileptic Drug‐Induced Cutaneous Reactions in Han Chinese , 2007, Epilepsia.
[20] M. Mockenhaupt,et al. Variability in the clinical pattern of cutaneous side‐effects of drugs with systemic symptoms: does a DRESS syndrome really exist? , 2007, The British journal of dermatology.
[21] H. Yazaki,et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. , 2007, AIDS.
[22] A. Romano,et al. Gene–gene interactions of IL13 and IL4RA variants in immediate allergic reactions to betalactam antibiotics , 2006, Pharmacogenetics and genomics.
[23] C. Carcassi,et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients , 2006, AIDS.
[24] P. Demoly,et al. IL‐10 promoter and IL4‐Rα gene SNPs are associated with immediate β‐lactam allergy in atopic women , 2006 .
[25] S. Jee,et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions , 2006, Pharmacogenetics and genomics.
[26] M. Schumacher,et al. A marker for Stevens-Johnson syndrome …: ethnicity matters , 2006, The Pharmacogenomics Journal.
[27] S. Mallal,et al. Clinical and immunogenetic correlates of abacavir hypersensitivity , 2005, AIDS.
[28] J. Roujeau. Clinical heterogeneity of drug hypersensitivity. , 2005, Toxicology.
[29] Yuan-Tsong Chen,et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[30] C. Moore,et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts , 2005, AIDS.
[31] Hailing Qiao,et al. Specific serum IgE levels and FcɛRIβ genetic polymorphism in patients with penicillins allergy , 2004, Allergy.
[32] A. Roses,et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. , 2004, Pharmacogenomics.
[33] S. Knowles,et al. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. , 2002, AIDS.
[34] L. Naldi,et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. , 2002, Archives of dermatology.
[35] S. Wolfe,et al. Timing of new black box warnings and withdrawals for prescription medications. , 2002, JAMA.
[36] Clive E. Bowman,et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.
[37] C. Moore,et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.
[38] L. Vaillant,et al. Acute generalized exanthematous pustulosis (AGEP) – A clinical reaction pattern , 2001, Journal of cutaneous pathology.
[39] Theresa Anderson,et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis , 1995 .
[40] R. Stern,et al. Severe adverse cutaneous reactions to drugs. , 1994, The New England journal of medicine.
[41] S. Mallal,et al. HLA-B*35 is associated with nevirapine hypersensitivity in the contemporary Western Australian HIV cohort study , 2010 .
[42] D. Bandyopadhyay,et al. Indian J Dermatol Venereol Leprol , 2010 .
[43] L. Naldi,et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. , 2008, Journal of the American Academy of Dermatology.
[44] M. Mockenhaupt. Epidemiology and Causes of Severe Cutaneous Adverse Reactions to Drugs , 2007 .
[45] B. Thiers. Medical Genetics: A Marker for Stevens-Johnson SyndromeChung W-H, Hung S-I, Hong H-S, et al (Chang Gung Mem Hosp, Taipei, Taiwan; Inst of Biomedical Sciences, Taipei, Taiwan) Nature 428:486, 2004§ , 2006 .
[46] R. Stern,et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. , 1993, Archives of dermatology.